Value Unlocked: BMS Buying Padlock For Up To $600m
This article was originally published in Scrip
Two years, $18m and a big pharma buyout for up to $600m? That's a great return for investors in Padlock Therapeutics Inc., a biotech firm that raised a single venture capital round in late 2014 to develop novel treatments for autoimmune diseases before Bristol-Myers Squibb Co. agreed to buy the company.
Register for our free email digests: